Merck nabs FDA blessing for Grastek immunotherapy; Akorn to sell 5 drugs for antitrust OK on Hi-Tech buyout; U.K. hep C charity calls Gilead drug unaffordable;

@FiercePharma: Top-read on FiercePharma Monday: New attention disorder could equal a big new ADHD drug market. But is it legit? Story | Follow @FiercePharma

@TracyStaton: Juicy trade-secrets dispute between Bristol-Myers + its ad agency and an account manager who jumped ship. More from MediaPost | Follow @TracyStaton

@EricPFierce: A Patheon (now DPx) plant that had been up for sale gets a $300M infusion to make Exparel for Pacira. Article | Follow @EricPFierce

@CarlyHFierce: J&J Q1 sales tally 18.1 billion... read more here. Release | Follow @CarlyHFierce

> Merck & Co. ($MRK) won FDA approval for its new, oral grass-pollen allergy immunotherapy, Grastek, hot on the heels of a similar rival from Stallergenes. Report

> Generics maker Akorn Enterprises ($AKRX) nabbed U.S. antitrust approval to buy rival Hi-Tech Pharmacal ($HITK), provided it sells off five of its copycat products. Report

> The U.K.'s Hepatitis C Trust called Gilead Sciences' ($GILD) new treatment for the disease cost-effective, but said it's not "affordable" for use by the country's National Health Service. Report

> Mylan ($MYL) and Prosonix teamed up to develop generic versions of GlaxoSmithKline's ($GSK) inhaled asthma drugs Flixotide and Flovent. Release

> Mylan ($MYL) and Actavis ($ACT) wrapped up a patent fight over Actavis' branded contraceptive Generess FE, in a deal that allows Mylan to launch its generic version in June 2015. Release

> Sanofi's ($SNY) Indian unit tapped N. Rajaram to head up its pharmaceuticals operations in the country. Report

Medical Device News

@FierceMedDev: Med tech VC Santé wraps up a $139M healthcare fund. Piece | Follow @FierceMedDev

@VarunSaxena2: Abbott's diabetes biz hit with its third Class I recall in a year. News | Follow @VarunSaxena2

@EmilyWFierce: Devices approved for pediatric use weren't tested in children first, new study finds. More | Follow @EmilyWFierce

@MichaelGFierce: ICYMI: 'Computer' made with DNA nanorobots delivers compounds in live cockroach. Story | Follow @MichaelGFierce

> TransEnterix raises $50M for surgical robot. Article

> Medtronic strikes back in its TAVR patent battle with Edwards. Story

Biotech News

@FierceBiotech: GlaxoSmithKline wins an FDA nod for its new #diabetes drug. More | Follow @FierceBiotech

@JohnCFierce: Little Lexicon posts positive diabetes data as rival pharma giants race ahead. Story | Follow @JohnCFierce

@DamianFierce: J&J's diagnostics business slipped another 7.1% on its way out the door. News | Follow @DamianFierce

@EmilyMFierce: New vaccine could guard against common birth defect-causing virus. Article | Follow @EmilyMFierce

> Merck bags FDA approval for its grass pollen pill Grastek. Story

> Roche adds a slate of PhIII schizophrenia trial failures to bitopertin's obituary. More

> Startup AAVLife sets sights on ataxia with $12M and a novel gene therapy. Article

Biotech Research News

> Essential immune organ regenerated in mice. Story

> 3-D printed tumor mimics cancer better than 2-D model. Piece

> High protein levels linked to cell death in Parkinson's. More

> New vaccine could guard against common birth defect-causing virus. Article

> Plush 'carpets' of Silly Putty ingredient help stem cells grow. Feature

> UCSF rolls out patient database to boost brain research. Item

Pharma Manufacturing News

> Teva recalling more than 1M bottles of generic Cymbalta. Story

> FDA tags yet another Indian drugmaker, Canton Labs, with ban. More

> Plant that Patheon wanted to sell gets $300M investment. Article

> Impax believes manufacturing issues are fixed. News

> FDA bans Baxter plant that makes saline solution. Item

> ViiV recalls 1,000 bottles of Tivicay for cross-contamination. Report

And Finally... Doctors are prescribing opioid painkillers to pregnant women in large numbers, despite lack of proof that they are safe. Report

Suggested Articles

After Purdue’s record opioid settlement, more deals could be on the way. But that doesn’t mean all defendants are prepared to go quietly.

Now in their third quarter on the market, Gilead's own Epclusa and Harvoni generics have together grabbed more than 20% of the U.S. hep C market.

Purdue is seeking bankruptcy after inking a $10 billion-plus opioid settlement with thousands of cities and counties, plus two dozen states.